Navigation Links
Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting

tions, risks that the Chemical, Manufacturing and Controls section of Discovery's New Drug Application will not satisfy the FDA, risks relating to the ability of Discovery or Discovery's third party manufacturers and development partners to manufacture or provide Discovery with adequate supplies of drug substances and expertise for completion of any of Discovery's clinical studies, risks related to the ability of Discovery and its collaborators to develop, manufacture and successfully commercialize products that combine Discovery's drug products with innovative aerosolization technologies, risks relating to drug manufacturing by Discovery, risks relating to the significant, time-consuming and costly research, development, pre-clinical studies, clinical testing and regulatory approval process for any products that Discovery may develop independently or with Discovery's collaboration arrangements, risks relating to the development by other companies of competing therapies and/or technologies, risks relating to reimbursement and health care reform, and risks relating to securities, product liability and other litigation. Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials, even after obtaining promising earlier trial results. Data obtained from tests are susceptible to varying interpretations, which may delay, limit or prevent regulatory approval. Those associated risks and others are further described in Discovery's filings with the Securities and Exchange Commission including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto.

Company Contact: Lisa Caperelli, Investor Relations 215-488-9413


'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Discoverys KL-4 Surfactant Technology Demonstrates Novel Anti-Inflammatory Properties
3. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:8/29/2014)... SPRING, Md. , Aug. 29, 2014  United ... that the U.S. District Court for the District of ... its favor in the company,s case against Sandoz, Inc. ... Judge Peter Sheridan ruled that U.S. Patent ... Inc., and enjoined Sandoz from marketing its generic product ...
(Date:8/29/2014)... August 29, 2014 According ... Product & Services (Equipment, Reagent, Primer, Probe, Custom ... PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) - ... global Oligonucleotide Synthesis Market is expected to reach ... 2014, growing at a CAGR of 9.8% from ...
(Date:8/29/2014)... 2014  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... intends to release its financial results for the fiscal ... after market trading ends on Tuesday, September 9, 2014. ... for 4:30 p.m. U.S. EDT on Tuesday, September 9, ... review the Company,s financial results, commercial partnerships, and future ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
... certain mutations enable specific cells in the,retina to ... suggests deliberate,genetic manipulations might coax an injured brain ... Investigators at St.,Jude Children,s Research Hospital have ... cancer retinoblastoma, disproving a long-standing principle of,nerve growth ...
... Oct. 18 CEL-SCI CORPORATION,(Amex: CVM ) ... is a featured presenter at the International Society ... Mr. Kersten will present on the "New Realities ... p.m. (Eastern Daylight,Time). In April 2007, CEL-SCI ...
Cached Medicine Technology:St. Jude Identifies the Specific Cell That Causes Eye Cancer, Disproving Long-Held Theory 2St. Jude Identifies the Specific Cell That Causes Eye Cancer, Disproving Long-Held Theory 3CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase 2
(Date:8/29/2014)... San Francisco, CA (PRWEB) August 30, 2014 ... the 10 best web conference providers in the online ... Amongst the list were global leaders Webex, GotoMeeting and ... in the industry users have to determine which provider ... Essentially, web conference businesses search for compelling consumer ...
(Date:8/29/2014)... 2014 Honey Gifts, premium Vancouver adult ... now be selling purse-sized adult toys and erotic products. ... they can be carried in a woman’s purse with ... range at Honey Gifts is also leak-free and will ... rechargeable batteries are common characteristics of Honey Gifts’ portable ...
(Date:8/29/2014)... 29, 2014 Sansego is ... an interactive online community, and a range of personalized ... all the way to professional athletes. Crowie has brought ... been with him throughout the majority of his triathlon ... in the triathlon public. , Sansego provides the following:, ...
(Date:8/29/2014)... Work is the recipient of a ... Drug Abuse (NIDA) at the National Institutes of Health (NIH) ... use. Additionally, the grant provides resources to create the infrastructure ... use has increased steadily since 2007 according to NIDA, as ... and more available opioid. , A primary project at ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Ethane Web ... recently launched a new service named HTML web design. ... based service. Before tailoring the service, Ethane Web Technologies ... other companies. The company has done its best efforts ... and able to deliver outstanding results to clients. ...
Breaking Medicine News(10 mins):Health News:Top10InAction Reveals Best Web Conference Providers 2Health News:Honey Gifts Now Provides Purse Sized Adult Toys in Vancouver 2Health News:5 x World Champion Triathlete, Craig “Crowie” Alexander, Launches Online Triathlon Coaching Company – Sansego 2Health News:5 x World Champion Triathlete, Craig “Crowie” Alexander, Launches Online Triathlon Coaching Company – Sansego 3Health News:$1.25 million NIH grant to aid research on impact of heroin use 2Health News:Ethane Web Technologies Launches a New Web Design Service 2
... ... DSPanel today announced the availability of their latest ... DSPanel announced the availability of DSPanel Performance Canvas 2.2 with Planning, ... designed to be used as an accompaniment to Sharepoint 2010 and ...
... ... 140-2 Level Certification , ... (PRWEB) May 26, 2010 -- bTrade announced today that the company’s Managed ... Transfer solutions have received the Federal Information Processing Standards (FIPS) 140-2 (Level 1) validation, ...
... ... special section dedicated to prescription sunglasses , ... New Jersey (PRWEB) May 26, 2010 -- With summer quickly ... in selling prescription glasses has been selling prescription sunglasses since ...
... ... take over as President of the company effective July 1st, 2010. , ... Waterloo, IA (Vocus) May 26, 2010 -- John Spragle recently announced ... VGM Insurance,s plan for my successor. Effective June 1, 2010, Tom Jones will be joining VGM ...
... ... and Curcumin have demonstrated anti-tumor properties and may serve as important therapeutic agents in ... anti-cancer chemicals has been the focus of US based Biomedical Company, Millennium Bioceutics with ... ...
... used a magnetic resonance imaging (MRI) technique called continuous ... patterns in schizophrenic patients quickly and without using radiation ... edition and July printed issue of the journal ... technique that can help reduce the cost and complexity ...
Cached Medicine News:Health News:DSPanel's New Mobile Analytics Server for Business Intelligence: Data Analysis, Monitoring and Planning When and Where You Need It 2Health News:DSPanel's New Mobile Analytics Server for Business Intelligence: Data Analysis, Monitoring and Planning When and Where You Need It 3Health News:bTrade Earns Stringent Government Data Security Certification 2Health News:bTrade Earns Stringent Government Data Security Certification 3Health News:GlassesUSA.com Launches Section for Prescription Sunglasses 2Health News:VGM Insurance President Passes the Baton 2Health News:Natural Chemicals Act As Cancer Killers 2Health News:Blood flows differently through the brains of schizophrenic patients 2
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
The upper body blanket covers the upper torso, arms, neck, and head of the patient....
The Electri-Cool® II is the premier choice when it comes to localized cold therapy systems. system offers the widest variety of application-specific pads and wraps, for your convenience....
Complete Cataract Competence , OPMI VISU 140 is compact, good and economical. It's everything a cataract specialist needs today....
Medicine Products: